Impact of pain and nonpain co-morbidities on opioid use in women with endometriosis

Georgine Lamvu, Ahmed M Soliman, Beverly Johns, Jamie B Vora, Jamie Vora, Stephanie J Estes
Journal of comparative effectiveness research · 2020 · vol. 10(1) , pp. 17–27 · doi:10.2217/cer-2020-0181 · PMID:33140993 · W3095899946
article OA: hybrid CC0
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This retrospective analysis found that women with endometriosis who used opioids before diagnosis were more likely to receive them postdiagnosis, with comorbidities increasing the risk of prolonged opioid supply.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Aim: To evaluate impact of co-morbidities on opioid use in endometriosis. Patients & m ethods: This was a retrospective analysis of data obtained from the Symphony Health database (July 2015–June 2018), which contains medical and pharmacy claims information on 79,947 women with endometriosis. Relative risk (RR) of postdiagnosis opioid use and supply duration associated with baseline co-morbidities were determined. Results: Women with endometriosis using opioids at baseline were 61% more likely to receive opioids postdiagnosis (RR: 1.61; 95% CI: 1.59–1.63). Risk of prolonged opioid supply postdiagnosis was highest for those with prolonged supply at baseline (RR: 21.14; 20.14–22.19), and was 1.32 (1.26–1.38) for patients with ≥1 co-morbidity, 1.37 (1.31–1.43) for pain co-morbidities and 1.07 (1.04–1.11) for psychiatric co-morbidities. Conclusion: Risk of opioid use after endometriosis diagnosis was greater in patients who used opioids before diagnosis. Risk of prolonged opioid use was greater if co-morbidities existed before diagnosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Analgesics, Opioid Analgesics, Opioid Endometriosis Endometriosis Endometriosis Endometriosis Female Humans Morbidity Pain Retrospective Studies

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (31)

Source provenance

europepmc
last seen: 2026-06-17T06:13:18.893374+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:36.268089+00:00
License: CC0 · commercial use OK